185 results about "Lymphoid Tumor" patented technology

Antibody binding assays and radiolabeling kits are disclosed for radiolabeling and testing therapeutic antibodies in the commercial setting. In particular, the kits are designed for making and evaluating radiolabeled anti-CD20 conjugates to be used for the treatment and imaging of B cell lymphoma tumors. All kit reagents are sterile and are designed to achieve a high level of antibody radiolabeling and product stability with results which are highly reproducible.

The present invention relates to antibodies or fragments thereof that specifically bind FcγRIIB, particularly human FcγRIIB, with greater affinity than said antibodies or fragments thereof bind FcγRIIA, particularly human FcγRIIA. The present invention also provides the use of an anti-FcγRIIB antibody or an antigen-binding fragment thereof, as a single agent therapy for the treatment, prevention, management, or amelioration of a cancer, preferably a B-cell malignancy, particularly, B-cell chronic lymphocytic leukemia or non-Hodgkin's lymphoma, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention.

The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scFV derived from a BCMA monoclonal antibody, conferring specific immunity against BCMA positive cells. The engineered immune cells endowed with such CARs are particularly suited for treating lymphomas, multiple myeloma and leukemia.

Methods and compositions are provided for the identification of stem cells and cancer stem cells. β-catenin is also identified as a target for the development of therapeutic moieties against hematopoietic tumors, i.e. leukemia and lymphoma cells, which may include screening assays directed at β-catenin, or members of the β-catenin signaling pathway. Cellular proliferation in hematopoietic cells can be altered by introducing stabilized β-catenin into a hematopoietic cell that is altered in its ability to undergo apoptosis but which is not fully transformed. The immortalized cells are useful in screening assays, and in the analysis of pathways by which hematopoietic cells undergo transformation.

The invention relates to combinations comprising an HDAC inhibitor and an immunomodulatory drug for the treatment of lymphoma in a subject in need thereof. Also provided herein are methods for treating lymphoma in a subject in need thereof comprising administering to the subject an effective amount of one of the above combinations.

The present invention discloses an anti-tumor compound and its preparation method,application, and pharmaceutical compositions. The anti-tumor compound is a 4 - nitro-substituted benzyl group ifosfamide ester prodrug thereof, or pharmaceuticallysalt, or solvate thereof of the structure of formula I. The structure of formula I. The present invention has the following advantage of being used for the treatment or prevention of mammalian tumor-related diseases, such as leukemia, hemangioma, glioma, Kaposi's sarcoma, ovarian cancer, breast cancer, lung cancer, pancreatic cancer, lymphoma, prostate, colon and skin tumors and their complications.

The synthesis of deuterated analogues of rapamycin is disclosed together with a method for use for inducing immunosupression and in the treatment of transplantation rejection, graft vs host disease, autoimmune diseases, diseases of inflammation leukemia/lymphoma, solid tumors, fungal infections, hyperproliferative vascular disorders. Also described is a method for the synthesis of water soluble deuteratred rapamycin compounds and their use as described above.

The present invention relates to polypeptide compositions which bind to cell surface epitopes and, in multivalent forms, cause or lead to the killing of cells including lymphoid tumor cells, and in the case of monovalent forms, cause immunosuppression or otherwise inhibit activation of lymphocytes. The invention further relates to nucleic acids encoding the polypeptides, methods for the production of the polypeptides, methods for killing cells, methods for immunosuppressing a patient, pharmaceutical, diagnostic and multivalent compositions and kits comprising the polypeptides and uses of the polypeptides.

The present invention relates to an injection vinorebin powder injection preparation and its preparation method. It is made up by using vinorebin as main medicine or adding at least one of dextran, mannitol and sorbitol as filling agent, using at least one of solvents of water for injection, acetone and ethyl alcohol to dissolve them to obtain solution, then decolouring with active carbon, filtering by using microporous filtering film, then dehydration drying by using freeze-drying or reduced pressure drying to obtain the invented powder injection for curing the diseases of non-small cell lung cancer, mammary cancer, oophoroma and lymphoma, etc.

The invention discloses a B7.1-CD19scFv merge gene engineering protein and usage to treat B lymphocyte leukosis, lymph tumor, which comprises the following parts: human B7.1 external cell area, antihuman CD19 monoclonal antibody heavy chain and light chain variable area gene.

The invention provides a method for preparing a PD1 humanized BALB/c mouse model, this method utilizes CRIPSR/Cas9 technology, most extracellular domains of mouse PD1 were humanized by homologous recombination through constructing a targeting carrier, and the intracellular domains were still mouse sequences, and the intracellular signal transduction ability was preserved. The humanization model constructed by this method maximized the human domain (antibody binding domain) and avoided missing the effective antibody. At the same time, PD1 humanized model based on BALB/c can be inoculated with colorectal cancer, liver cancer, melanoma, breast cancer, kidney cancer and lymphoma to satisfy various solid tumor cell line types, and expand the application of the widespread.

A biomarker, method, test kit, and diagnostic system for detecting the presence of lymphoma in a person are disclosed. The lymphoma may be Hodgkin's lymphoma or non-Hodgkin's lymphoma. The person may be a high-risk subject. In one embodiment, a plasma sample from a person is obtained. The level of at least one protein listed in Table S3 in the plasma sample is measured. The level of at least one protein in the plasma sample is compared with the level in a normal or healthy subject. The lymphoma is diagnosed based upon the level of the at least one protein in the plasma sample in comparison to the normal or healthy level.

The invention discloses application of a sugar-containing platinum complex in the preparation of medicines for preventing and treating tumor. The sugar-containing platinum complex is shown as the formula (I). The test proves that the sugar-containing platinum complex shown as the formula (I) can prevent and treat cancer of mammals, such as lung cancer, colon cancer, head and neck cancer, prostatic cancer, breast cancer, ovarian cancer, cervical cancer, leukemia, lymphoma, skin cancer, pancreatic cancer, liver cancer, bladder cancer, esophageal cancer, stomach cancer, male genital organ cancer, bone cancer and the like of the mammals, in particular can prevent and treat lung cancer, colon cancer, head and neck cancer, prostatic cancer, breast cancer, ovarian cancer, cervical cancer, leukemia, lymphoma, skin cancer, pancreatic cancer, liver cancer, bladder cancer, esophageal cancer, stomach cancer, male genital organ cancer or bone cancer of human beings.

The present invention provides combination immunotherapy for Non-Hodgkin's Lymphoma. In one embodiment, the combination immunotherapy first provides for the administration of a monoclonal antibody directed to a non-idotypic portion of a lymphoma cell surface immunoglobulin (e.g. a framework region of a variable region). The combination immunotherapy next provides for the administration of an immunogenic composition comprising at least a portion of the same lymphoma cell surface immunoglobulin, whether an idiotypic portion or non-idiotypic portion.

The present invention relates to 2′-Fluoro-6′-methylene carbocyclic nucleosides, pharmaceutical compositions containing these nucleosides and their use in the treatment or prophylaxis of a number of viral infections and secondary disease states and conditions thereof, especially including Hepatitis B virus (HBV) and secondary disease states and conditions thereof (cirrhosis and liver cancer), Heptatitis C virus (HCV), Herpes Simplex virus I and II (HSV-1 and HSV-2), cytomegalovirus (CMV), Varicella-Zoster Virus (VZV) and Epstein Barr virus (EBV) and secondary cancers which occur thereof (lymphoma, nasopharyngeal cancer, including drug resistant (especially including lamivudine and/or adefovir resistant) and other mutant forms of these viruses, especially HBV.

Conventional cancer immunotherapy falls short at efficiently expanding T cells that specifically target cancerous cells in numbers sufficient to significantly reduce the tumor size or cancerous cell number in vivo. To overcome this limitation, provided herein are nanoparticles coated with MHC class I and/or class II molecules presenting tumor-specific antigens and co-stimulatory molecules and their use to expand antigen-specific anti-tumorigenic T cellsto levels not achieved in current immunotherapeutic techniques. These antigen-specific anti-tumorigenic T cells include cytotoxic T cells, effector T cells, memory T cells, and helper T cells that are necessary to initiate and maintain a substantial immune response against metastatic or non- metastatic cancerous, pre-cancerous, or neoplastic cells in vivo.; The present invention describes a systemic approach to targeting cancerous or pre-cancerous cells that are circulating cells, as in lymphomas, migratory metastatic cells, and solid tumors.

The invention provides a tumor eliminating powder, including: Uroctea 1-10 shares, batryticated silkworm 2-8 shares, pod 2-15 shares, vermilion 1-6 shares, Fructus Ziziphi Jujubae 5-20 shares, spider 3-12 shares, and also including: Chinese angelica 3-12 shares, Mamyflower Gueldemstaedtid Herb 3-15 shares, and Commiphora Myrrha 1-10 shares. It can be applied to cure proliferation of mammary gland, mastitis, mastadenoma, poisoned sore, thyroid tumor, lymphoma, etc, and its curative effect is good and it has no toxicity and side effect.

The invention provides a traditional Chinese medicine composition for treating lymphoma. The traditional Chinese medicine composition comprises the following active ingredients in parts by weight: 4-20 parts of dried tangerine peels, 3-12 parts of selfheal, 3-15 parts of radix astragali, 2-10 parts of herba corydalis bungeanae, 3-12 parts of atractylodes, 1-5 parts of centipede, 1-5 parts of indigo naturalis, 1-5 parts of bombyx batryticatus, 3-15 parts of fructus hordei germinatus, 3-12 parts of rhizoma paridis, 3-9 parts of angelica sinensis, 3-12 parts of solanum lyratum thumb, 1-8 parts of fructus forsythia, 3-15 parts of rhizoma anemarrhenae, 1-6 parts of hirudo, and 4-10 parts of radix scrophulariae. The traditional Chinese medicine composition integrates the effects of clearing away heat and toxic materials, removing stasis and dispersing swelling, eliminating dampness and eliminating phlegm, strengthening spleen and regulating qi, promoting blood circulation to remove blood stasis, and promoting qi circulation and relieving pain, thus inhibiting or killing cancer cells, eliminating cancer focus, improving the immunity of the organism, preventing the tumor metastasis and relapse, and being clinically used for treating lymphoma. According to the formula, the traditional Chinese medicine composition not only has a good curative effect on the lymphoma through experiment tests, but also is simple in formula and low in cost.